Open-label Trial of Leukine in Active Crohn's Disease
Open-label Trial of Leukine® (Sargramostim), A Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), in Active Crohn's Disease
3 other identifiers
interventional
378
10 countries
167
Brief Summary
The purpose of this study is to establish a safety profile sargramostim administered in 8 week cycles to adult patients with active Crohn's disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started Feb 2003
Typical duration for phase_2
167 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2003
CompletedFirst Submitted
Initial submission to the registry
September 13, 2005
CompletedFirst Posted
Study publicly available on registry
September 21, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2006
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2006
CompletedDecember 4, 2013
December 1, 2013
3.8 years
September 13, 2005
December 2, 2013
Conditions
Outcome Measures
Primary Outcomes (1)
To establish a safety profile for long-term, repeated cycles of sargramostim administered to subjects with Crohn's disease.
Not applicable for this outcome
Secondary Outcomes (3)
Crohn's disease activity
After successive 8-week cycles of treatment
Duration of clinical remission and time to disease flare
After successive cycles of sargramostim therapy
Patient compliance
After successive cycles of sargramostim therapy
Study Arms (1)
Arm 1
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- Able to provide informed consent
- Participated in a previous study of sargramostim in Crohn's disease within the past 12 months
- Subjects who participated in protocols excluding concomitant steroid use:
- Must have moderately to severely active Crohn's disease at time of screening (CDAI score \>/= 220 points and less than or equal to 475 points)
- Must be receiving less than or equal to 40 mg prednisone (or equivalent) daily at time of screening if treated with corticosteroids between completing their previous sargramostim study and entry into this study and be able to taper to less than or equal to 7.5 mg daily within one treatment cycle
- Subjects who participated in Protocol 307501
- Must have active Crohn's disease (CDAI score \> 150 points and less than or equal to 450 points) if completely withdrawn from CS use
- Must be receiving less than or equal to 40 mg prednisone (or equivalent) daily at time of screening, be able to taper to less than or equal to 7.5 mg daily within 2 treatment cycles, and have a CDAI score less than or equal to 450 points if not completely withdrawn from CS use
- Have a negative serum pregnancy test within 2 weeks prior to receiving initial dose of sargramostim in female subjects of child-bearing potential (optional - may be waived by the investigator if the subject has had no interruption in contraception method since participation in the previous study)
- Agree to use of an adequate method of contraception throughout the study period for sexually-active males and females of childbearing potential
- Able to self-inject sargramostim or have a designee who can do so
- Able to comply with protocol requirements
- Have a negative stool exam if subject received a course of antibiotics since participation in the previous study
You may not qualify if:
- Pregnant or breastfeeding female
- Need for gastrointestinal (GI) surgery for active GI bleeding, peritonitis, intestinal obstruction, or intra-abdominal or perianal abscess requiring surgical drainage
- Gastrointestinal surgery within the prior 6 months
- Symptoms of bowel obstruction or confirmed evidence of a clinically-significant stricture within the last 6 months that has not been surgically corrected
- Serum creatinine greater than or equal to 2.0 mg/dL
- Use of licensed/registered anti-tumor necrosis factor (TNF) therapy such as infliximab within 8 weeks prior to first dose of study drug in this trial
- Use of any of the following medications within 4 weeks prior to receiving the first dose of study drug: 6-mercaptopurine, azathioprine, cyclophosphamide, methotrexate, mycophenolate mofetil, tacrolimus, cyclosporine, or thalidomide
- Use of any experimental agent in a clinical trial since participating in a sargramostim trial
- History of allergy to yeast products or sargramostim
- Psychiatric illness or substance abuse that would interfere with ability to comply with protocol requirements or give informed consent
- Clinically important primary disease unrelated to Crohn's disease
- Prior exposure to natalizumab (Tysabri)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (167)
Unknown Facility
Birmingham, Alabama, 35209, United States
Unknown Facility
Scottsdale, Arizona, 85259-5404, United States
Unknown Facility
Berkeley, California, 94705, United States
Unknown Facility
Los Angeles, California, 90067, United States
Unknown Facility
Orange, California, 92868, United States
Unknown Facility
San Francisco, California, 94115, United States
Unknown Facility
San Francisco, California, 94117, United States
Unknown Facility
Tarzana, California, 91345, United States
Unknown Facility
Aurora, Colorado, 80045, United States
Unknown Facility
Englewood, Colorado, 80110, United States
Unknown Facility
Lakewood, Colorado, 80215, United States
Unknown Facility
Littleton, Colorado, 80120, United States
Unknown Facility
Washington D.C., District of Columbia, 20010, United States
Unknown Facility
Boca Raton, Florida, 33486, United States
Unknown Facility
Clearwater, Florida, 33765, United States
Unknown Facility
Gainesville, Florida, 32608-1197, United States
Unknown Facility
Gainesville, Florida, 32610-0254, United States
Unknown Facility
Hollywood, Florida, 33021, United States
Unknown Facility
Jacksonville, Florida, 32224, United States
Unknown Facility
Jacksonville, Florida, 32256, United States
Unknown Facility
North Miami Beach, Florida, 33162, United States
Unknown Facility
Winter Park, Florida, 32789, United States
Unknown Facility
Atlanta, Georgia, 30342, United States
Unknown Facility
Chicago, Illinois, 60637-1470, United States
Unknown Facility
Indianapolis, Indiana, 46202, United States
Unknown Facility
Indianapolis, Indiana, 46237, United States
Unknown Facility
Lexington, Kentucky, 40536, United States
Unknown Facility
Louisville, Kentucky, 40202, United States
Unknown Facility
Lake Charles, Louisiana, 70601, United States
Unknown Facility
Metairie, Louisiana, 70001, United States
Unknown Facility
Slidell, Louisiana, 70458, United States
Unknown Facility
Annapolis, Maryland, 21401, United States
Unknown Facility
Hagerstown, Maryland, 21740, United States
Unknown Facility
Towson, Maryland, 21204, United States
Unknown Facility
Boston, Massachusetts, 02114-2696, United States
Unknown Facility
Chesterfield, Michigan, 48047, United States
Unknown Facility
Troy, Michigan, 48098, United States
Unknown Facility
Plymouth, Minnesota, 55446, United States
Unknown Facility
Mexico, Missouri, 65265, United States
Unknown Facility
St Louis, Missouri, 63110, United States
Unknown Facility
Billings, Montana, 59107, United States
Unknown Facility
Lincoln, Nebraska, 68503, United States
Unknown Facility
Lebanon, New Hampshire, 03756-0001, United States
Unknown Facility
Berlin, New Jersey, 08009, United States
Unknown Facility
Great Neck, New York, 11021, United States
Unknown Facility
Mineola, New York, 11501-3987, United States
Unknown Facility
New York, New York, 10029, United States
Unknown Facility
Rochester, New York, 14607, United States
Unknown Facility
Syracuse, New York, 13210, United States
Unknown Facility
Asheville, North Carolina, 28801, United States
Unknown Facility
Chapel Hill, North Carolina, 27514, United States
Unknown Facility
Charlotte, North Carolina, 28207, United States
Unknown Facility
Greensboro, North Carolina, 27403, United States
Unknown Facility
Wilmington, North Carolina, 28401, United States
Unknown Facility
Winston-Salem, North Carolina, 27103, United States
Unknown Facility
Winston-Salem, North Carolina, 27157, United States
Unknown Facility
Cincinnati, Ohio, 45219, United States
Unknown Facility
Cincinnati, Ohio, 45220, United States
Unknown Facility
Cincinnati, Ohio, 45242, United States
Unknown Facility
Oklahoma City, Oklahoma, 73104, United States
Unknown Facility
Tulsa, Oklahoma, 74104, United States
Unknown Facility
Portland, Oregon, 97213, United States
Unknown Facility
Portland, Oregon, 97225, United States
Unknown Facility
Portland, Oregon, 97239, United States
Unknown Facility
Hanover, Pennsylvania, 17331, United States
Unknown Facility
Lancaster, Pennsylvania, 17601-2644, United States
Unknown Facility
Philadelphia, Pennsylvania, 19104-2699, United States
Unknown Facility
Pittsburgh, Pennsylvania, 15212, United States
Unknown Facility
Pittsburgh, Pennsylvania, 15213-2592, United States
Unknown Facility
Sayre, Pennsylvania, 18840, United States
Unknown Facility
Charleston, South Carolina, 29425, United States
Unknown Facility
Columbia, South Carolina, 29203, United States
Unknown Facility
Bristol, Tennessee, 37620, United States
Unknown Facility
Jackson, Tennessee, 38305, United States
Unknown Facility
Kingsport, Tennessee, 37660, United States
Unknown Facility
Memphis, Tennessee, 38119, United States
Unknown Facility
Memphis, Tennessee, 38120, United States
Unknown Facility
Nashville, Tennessee, 37205, United States
Unknown Facility
Nashville, Tennessee, 37232, United States
Unknown Facility
Dallas, Texas, 75231, United States
Unknown Facility
Irving, Texas, 75061, United States
Unknown Facility
San Antonio, Texas, 78229, United States
Unknown Facility
Salt Lake City, Utah, 84132, United States
Unknown Facility
Charlottesville, Virginia, 22908, United States
Unknown Facility
Chesapeake, Virginia, 23320, United States
Unknown Facility
Danville, Virginia, 24541, United States
Unknown Facility
Norfolk, Virginia, 23502, United States
Unknown Facility
Richmond, Virginia, 23249-0002, United States
Unknown Facility
Bellevue, Washington, 98004, United States
Unknown Facility
Seattle, Washington, 98104, United States
Unknown Facility
Seattle, Washington, 98133, United States
Unknown Facility
Seattle, Washington, 98195, United States
Unknown Facility
Spokane, Washington, 99204, United States
Unknown Facility
Walla Walla, Washington, 99362, United States
Unknown Facility
Wenatchee, Washington, 98801, United States
Unknown Facility
Madison, Wisconsin, 53792, United States
Unknown Facility
Milwaukee, Wisconsin, 53215, United States
Unknown Facility
Milwaukee, Wisconsin, 53226, United States
Unknown Facility
Buenos Aires, Buenos Aires F.D., C1264AAA, Argentina
Unknown Facility
Garran, Australian Capital Territory, 2605, Australia
Unknown Facility
Concord, New South Wales, 2139, Australia
Unknown Facility
New Lambton Heights, New South Wales, 2305, Australia
Unknown Facility
Sydney, New South Wales, 2050, Australia
Unknown Facility
Sydney, New South Wales, 2200, Australia
Unknown Facility
Brisbane, Queensland, 4029, Australia
Unknown Facility
Brisbane, Queensland, 4101, Australia
Unknown Facility
Adelaide, South Australia, 5043, Australia
Unknown Facility
Launceston, Tasmania, 7250, Australia
Unknown Facility
Ballarat, Victoria, 3350, Australia
Unknown Facility
Frankston, Victoria, 3199, Australia
Unknown Facility
Melbourne, Victoria, 3065, Australia
Unknown Facility
Melbourne, Victoria, 3128, Australia
Unknown Facility
Parkville, Victoria, 3050, Australia
Unknown Facility
Prahran, Victoria, 3181, Australia
Unknown Facility
Fremantle, Western Australia, 6160, Australia
Unknown Facility
Penrith, 2751, Australia
Unknown Facility
Salvador, Estado de Bahia, 40110060, Brazil
Unknown Facility
Curitiba, Paraná, 80060-900, Brazil
Unknown Facility
Rio de Janeiro, Rio de Janeiro, 21949 900, Brazil
Unknown Facility
Porto Alegre, Rio Grande do Sul, Brazil
Unknown Facility
São Paulo, São Paulo, 05403-900, Brazil
Unknown Facility
São Paulo, São Paulo, 05651-901, Brazil
Unknown Facility
Edmonton, Alberta, T5H 4B9, Canada
Unknown Facility
Edmonton, Alberta, T6G 2B7, Canada
Unknown Facility
Kelowna, British Columbia, V1Y 2H4, Canada
Unknown Facility
Vancouver, British Columbia, V5Z 1H2, Canada
Unknown Facility
Vancouver, British Columbia, V6Z 2K5, Canada
Unknown Facility
Winnipeg, Manitoba, R3A 1R9, Canada
Unknown Facility
Hamilton, Ontario, L8N 3Z5, Canada
Unknown Facility
London, Ontario, N6A 5A5, Canada
Unknown Facility
Toronto, Ontario, M3N 2V7, Canada
Unknown Facility
Toronto, Ontario, M5G 1X5, Canada
Unknown Facility
Windsor, Ontario, N9A 1L9, Canada
Unknown Facility
Montreal, Quebec, H2W 1T8, Canada
Unknown Facility
Montreal, Quebec, H3A 1A1, Canada
Unknown Facility
Montreal, Quebec, H3G 1A4, Canada
Unknown Facility
Montreal, Quebec, H3T 1E2, Canada
Unknown Facility
Québec, Quebec, G1S 4L8, Canada
Unknown Facility
Milford, Auckland, 1309, New Zealand
Unknown Facility
Auckland, 1023, New Zealand
Unknown Facility
Christchurch, 8011, New Zealand
Unknown Facility
Hamilton, 3204, New Zealand
Unknown Facility
Lipetsk, Russia, 398055, Russia
Unknown Facility
Moskva, Russia, 105203, Russia
Unknown Facility
Samara, Russia, 443023, Russia
Unknown Facility
Moscow, 123154, Russia
Unknown Facility
Moscow, 129110, Russia
Unknown Facility
Moskva, 127015, Russia
Unknown Facility
Volgograd, 400107, Russia
Unknown Facility
Basel, Basel, 4031, Switzerland
Unknown Facility
Bern, Canton of Bern, 3010, Switzerland
Unknown Facility
Lausanne, Canton of Vaud, 1011, Switzerland
Unknown Facility
Donetsk, 83017, Ukraine
Unknown Facility
Kharkiv, 61001, Ukraine
Unknown Facility
Kiev, 03049, Ukraine
Unknown Facility
Lviv, 49044, Ukraine
Unknown Facility
Vinnitsa, 26014, Ukraine
Unknown Facility
Bristol, Avon, BS2 8HW, United Kingdom
Unknown Facility
London, Greater London, W12 0HS, United Kingdom
Unknown Facility
Salford, Greater Manchester, M6 8HD, United Kingdom
Unknown Facility
Edinburgh, Lothian, EH4 2XU, United Kingdom
Unknown Facility
Liverpool, Merseyside, L7 8XP, United Kingdom
Unknown Facility
Harrow, Middlesex, HA1 3UJ, United Kingdom
Unknown Facility
Cardiff, South Glamorgan, CF14 4XW, United Kingdom
Unknown Facility
Newcastle upon Tyne, Tyne and Wear, NE1 4LP, United Kingdom
Unknown Facility
London, WC1E 6AU, United Kingdom
Unknown Facility
Sheffield, S10 2JF, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Medical Monitor
Genzyme, a Sanofi Company
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 13, 2005
First Posted
September 21, 2005
Study Start
February 1, 2003
Primary Completion
December 1, 2006
Study Completion
December 1, 2006
Last Updated
December 4, 2013
Record last verified: 2013-12